November 19, 2006 – With its 55 point gain last week, the Centient Biotech 200™ moved over 4000 to 4009, its highest close since March 17. Breadth was very strong. The best performing issue in the biotech universe last week was a member of the recent IPO list, Vanda Pharma, which moved higher on positive Phase III data for its investigational sedative. On the IPO front, Hansen Medical and Emergent BioSolutions made their debuts, with mixed results. Dynavax rose on positive results for its allergy drug Tolamba; Sequenom was up on unusually heavy volume; Trimeris climbed after announcing a reorganization; Ariad had a net gain of 20%; and Poniard traded higher as it advances cancer drug picoplatin through clinical trials. More details...
